Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
- PMID: 15197495
- PMCID: PMC11034276
- DOI: 10.1007/s00262-004-0540-x
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
Abstract
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by the immune system under optimum conditions for activating adaptive and nonadaptive antitumor immune responses. Despite this capability, a large number of tumors continue to grow and evade recognition and/or destruction by the immune system. The limited success in current immunotherapeutic strategies may be due to a variety of reasons: failure of effector cells to compete with the growing tumor burden, production of humoral factors by tumors that locally block cytotoxicity, antigen/MHC loss, T-cell dysfunction, production of suppressor T cells-to name but a few causes for therapeutic ineffectiveness for the particular malignancy being treated. To optimize immunotherapy strategies, correction of immune-activating signals, eradication of inhibitory factors, and the evasion from newly developed immunoresistant tumor phenotypes need to be simultaneously considered.
Figures
Similar articles
-
Natural selection of tumor variants in the generation of "tumor escape" phenotypes.Nat Immunol. 2002 Nov;3(11):999-1005. doi: 10.1038/ni1102-999. Nat Immunol. 2002. PMID: 12407407 Free PMC article. Review.
-
Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?Cancer Immunol Immunother. 2004 Oct;53(10):879-92. doi: 10.1007/s00262-004-0577-x. Epub 2004 Jul 28. Cancer Immunol Immunother. 2004. PMID: 15338206 Free PMC article. Review.
-
T-cell death and cancer immune tolerance.Cell Death Differ. 2008 Jan;15(1):70-9. doi: 10.1038/sj.cdd.4402274. Epub 2007 Nov 16. Cell Death Differ. 2008. PMID: 18007660 Review.
-
CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.J Immunol. 2006 Mar 15;176(6):3374-82. doi: 10.4049/jimmunol.176.6.3374. J Immunol. 2006. PMID: 16517705
-
Strategies of tumor immune evasion.BioDrugs. 2005;19(6):347-54. doi: 10.2165/00063030-200519060-00002. BioDrugs. 2005. PMID: 16392887 Review.
Cited by
-
Hydralazine target: from blood vessels to the epigenome.J Transl Med. 2006 Feb 28;4:10. doi: 10.1186/1479-5876-4-10. J Transl Med. 2006. PMID: 16507100 Free PMC article.
-
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.J Clin Invest. 2010 Sep;120(9):3234-41. doi: 10.1172/JCI42672. Epub 2010 Aug 2. J Clin Invest. 2010. PMID: 20679728 Free PMC article.
-
Tumor stroma-associated antigens for anti-cancer immunotherapy.Cancer Immunol Immunother. 2006 May;55(5):481-94. doi: 10.1007/s00262-005-0070-1. Epub 2005 Oct 12. Cancer Immunol Immunother. 2006. PMID: 16220326 Free PMC article. Review.
-
GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.Cancer Immunol Immunother. 2007 Oct;56(10):1653-65. doi: 10.1007/s00262-007-0315-2. Epub 2007 Apr 5. Cancer Immunol Immunother. 2007. PMID: 17410360 Free PMC article.
-
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Nat Commun. 2023 May 31;14(1):3153. doi: 10.1038/s41467-023-38113-4. Nat Commun. 2023. PMID: 37258544 Free PMC article.
References
-
- Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett. 2003;90(2–3):103–22. - PubMed
-
- Speiser Cancer Immunol. 2003;3:12.
-
- Romero Pigment Cell Res. 2003;16:588. doi: 10.1034/j.1600-0749.2003.08353.x. - DOI
-
- Jager E, Jager D, Knuth A (2000) CTL-defined cancer vaccines in melanoma and other epithelial cancer. In: Stern PL, Beverely PCL, Carroll MW (eds) Cancer vaccines and immunotherapy. Cambridge University Press, Cambridge, pp 207
-
- Kaufmann HL, Schlorn J (2000) Vaccines in colon cancer. In: Stern PL, Beverely PCL, Carroll MW (eds) Cancer Vaccines and Immunotherapy. Cambridge University Press, Cambridge, p 107
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials